Noelle C. Dubiansky

Noelle Dubiansky is a partner in the firm’s Technology and Life Sciences groups. 

Ms. Dubiansky represents biotechnology, pharmaceutical, medical device, and other life science companies in a wide range of intellectual property and commercial transactions. She regularly advises private and public companies on complex commercial transactions, including strategic partnerships, licensing, technology acquisition, research and development collaborations, clinical testing, contract services, distribution and manufacturing agreements. Ms. Dubiansky also regularly counsels clients in connection with private financings, public offerings, spin-outs and M&A transactions with respect to intellectual property rights and operational risks.

Prior to joining Goodwin, Ms. Dubiansky was an associate in the Life Sciences practice group at Cooley LLP and previously, in the FDA group at Hyman, Phelps & McNamara. She joined Goodwin in 2014.

While attending law school, Ms. Dubiansky was named an Edward F. Hennessey Scholar.

A selection of her recent representations includes:

• Cullinan Pearl, a Cullinan Oncology company, in its strategic collaboration and license agreement with Zai Lab for its EGFR inhibitor, CLN-081, in Greater China, for $20 million upfront and up to $211 million in additional milestone payments.
• BridgeBio Pharma, Inc. in its joint venture with Maze Therapeutics to advance precision medicine to treat cardiovascular disease.
• Lacerta in its research, collaboration and licensing agreement with UCB Biopharma SRL (“UCB”) pursuant to which the parties will collaborate on developing novel gene therapies focused on a central nervous system disease with a high unmet need.
• insitro in its five-year, discovery collaboration with Bristol Myers Squibb focused on the discovery and development of novel therapies for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) for up to $2.1 billion.
• BridgeBio Pharma, Inc. and its affiliates Navire and QED on collaboration agreements with LianBio to expand BridgeBio’s global reach into China, the second-largest pharmaceutical market in the world, for up to $531.5 million.
• Blueprint Medicines Corporation on its global collaboration agreement with F. Hoffmann-La Roche LTD and Genentech, Inc. for the development and commercialization of pralsetinib, an investigational once-daily oral precision therapy for the treatment of people with cancer driven by oncogenic RET alterations, for an upfront payment of $775 million.
• Yumanity Therapeutics in its strategic research collaboration and license agreement with Merck focused on accelerating the development of new treatments for neurodegenerative diseases for $500 million.
• Corvidia Therapeutics in its acquisition by Novo Nordisk A/S for $725 million up front and up to $2 billion.
• Orionis Biosciences on its major drug discovery collaboration with Novartis, to discover and design novel small molecule therapeutics, such as protein degraders, across various therapeutic areas, by broadly leveraging Orionis’ Allo-Glue™ technology platform.
• Cerevance in its research collaboration with Takeda to identify novel target proteins for certain GI disorders, for a deal value of over $170 million on a per target basis. 
• Blackstone Life Sciences in its joint investment alongside Ferring Pharmaceuticals of over $570 million USD in nadofaragene firadenovec (rAd-IFN/Syn3), an investigational novel gene therapy in late-stage development for patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC).
• BridgeBio Pharma subsidiary Eidos Therapeutics in connection with a licensing agreement that grants Alexion an exclusive license to develop and commercialize AG10 in Japan.
• Century Therapeutics in its launch by Versant Ventures, Bayer and Fujifilm Cellular Dynamics Inc. (FCDI), which included $250 million in financing and a strategic partnership with FCDI.
• Akili Interactive Labs, a prescription digital medicine company, in its strategic partnership with Shionogi & Co.
• BridgeBio Pharma in its launch of its subsidiary, QED Therapeutics, including its in-license of infigratinib from Novartis.
• Bora Pharmaceuticals in connection with its acquisition of Impax Laboratories’ manufacturing facility in Taiwan.
• Moderna Therapeutics in its license and collaboration with AstraZeneca to co-develop and co-commercialize a mRNA therapeutic candidate for the treatment of heart failure. 
• Warp Drive Bio in its strategic collaboration with Roche to discover and develop novel classes of antibiotics, for a deal value of up to $387 million.
• Lysosomal Therapeutics in its exclusive option arrangement with Allergan plc. 
• BlueRock Therapeutics, a next-generation regenerative medicine company, in its $225 million financing by Bayer and Versant Ventures and seminal in-licenses and alliances with Memorial Sloan Kettering, the Centre for Commercialization of Regenerative Medicine and University Health Networks.
• Cerevance in its launch by Lightstone Ventures and Takeda Pharmaceutical, which included $36 million in financing and seminal in-licenses with Takeda, and in connection with its $45 million Series B financing. 
• Brammer Bio in its acquisition of a biologics manufacturing facility from Biogen.
• Galapagos NV in connection with its $2 billion strategic collaboration with Gilead Sciences, Inc., including $300 million upfront and a $425 million equity investment. The deal was named the Top Biopharmaceutical Licensing Deal at the 2016 Allicense Deals of the Year. 
• Voyager Therapeutics in its $845 million collaboration and option agreement with Genzyme Corp. to develop and commercialize novel gene therapies for central nervous system disorders.
• Warp Drive Bio in its strategic partnership with Sanofi.
• Lycera in connection with its $83 million global collaboration with Celgene Corporation.
• Teva in its $3.2 billion acquisition of Auspex Pharmaceuticals, Inc.
• Foundation Medicine in its collaboration agreement and equity transaction with Roche, with a total value in excess of $1 billion.
• Forma Therapeutics in its $600 million collaboration and option agreement with Celgene Corp., and follow-up $200 million strategic collaboration agreement, to develop and commercialize drug candidates to regulate protein homeostasis targets.*
• Molecular Partners AG in its strategic collaboration with Allergan with a total potential deal value of more than $1.4 billion.*

*Denotes experience prior to joining Goodwin.

Ms. Dubiansky was a 2021 and 2022 recommended lawyer for Patents: licensing by The Legal 500.

Ms. Dubiansky has been recognized as a Washington D.C. Super Lawyers “Rising Star” by the Washington Lawyer magazine.